These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 11981311)

  • 1. Respiratory syncytial virus infection: clinical features, management, and prophylaxis.
    Greenough A
    Curr Opin Pulm Med; 2002 May; 8(3):214-7. PubMed ID: 11981311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants.
    Joffe S; Ray GT; Escobar GJ; Black SB; Lieu TA
    Pediatrics; 1999 Sep; 104(3 Pt 1):419-27. PubMed ID: 10469764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP; Sinkin RA; Hall CB; Maniscalco WM; McConnochie KM
    Arch Pediatr Adolesc Med; 2000 Jan; 154(1):55-61. PubMed ID: 10632251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of respiratory syncytial virus infection with palivizumab.
    Thomas M; Bedford-Russell A; Sharland M
    Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    Meissner HC; Long SS;
    Pediatrics; 2003 Dec; 112(6 Pt 1):1447-52. PubMed ID: 14654628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A; Lau H; Magar R; Wang L; Devercelli G
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
    Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
    Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the cost of hospitalization for respiratory syncytial virus disease versus palivizumab prophylaxis in Canadian Inuit infants.
    Banerji A; Lanctôt KL; Paes BA; Masoud ST; Tam DY; Macdonald WA; Roberts A
    Pediatr Infect Dis J; 2009 Aug; 28(8):702-6. PubMed ID: 19461555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin.
    Thomas M; Bedford-Russell A; Sharland M
    Arch Dis Child; 2000 Aug; 83(2):122-7. PubMed ID: 10906017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Respiratory syncytial virus disease: update on treatment and prevention.
    Krilov LR
    Expert Rev Anti Infect Ther; 2011 Jan; 9(1):27-32. PubMed ID: 21171875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
    Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
    Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent Trends in RSV Immunoprophylaxis: Clinical Implications for the Infant.
    Acero-Bedoya S; Wozniak PS; Sánchez PJ; Ramilo O; Mejias A
    Am J Perinatol; 2019 Jul; 36(S 02):S63-S67. PubMed ID: 31238362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
    Resch B; Müller W
    Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of infections caused by respiratory syncytial virus.
    Swedish Consensus Group
    Scand J Infect Dis; 2001; 33(5):323-8. PubMed ID: 11440215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis for respiratory syncytial virus with respiratory syncytial virus-immunoglobulin intravenous among preterm infants of thirty-two weeks gestation and less: reduction in incidence, severity of illness and cost.
    Atkins JT; Karimi P; Morris BH; McDavid G; Shim S
    Pediatr Infect Dis J; 2000 Feb; 19(2):138-43. PubMed ID: 10694001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria.
    Resch B; Sommer C; Nuijten MJ; Seidinger S; Walter E; Schoellbauer V; Mueller WD
    Pediatr Infect Dis J; 2012 Jan; 31(1):e1-8. PubMed ID: 21960187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants.
    Ashkenazi-Hoffnung L; Dotan M; Livni G; Amir J; Bilavsky E
    Am J Infect Control; 2014 Sep; 42(9):991-5. PubMed ID: 25179332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn.
    Pediatrics; 1998 Nov; 102(5):1211-6. PubMed ID: 9794957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of respiratory syncytial virus infections in high-risk infants by monoclonal antibody (palivizumab).
    Groothuis JR; Nishida H
    Pediatr Int; 2002 Jun; 44(3):235-41. PubMed ID: 11982888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.